Boosting Immune Response With Copanlisib in Locally Advanced Unresectable Non-Small Cell Lung Cancer Receiving Durvalumab, A Phase Ib Study
Latest Information Update: 16 Feb 2024
At a glance
- Drugs Copanlisib (Primary) ; Durvalumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms LCD
- 12 Feb 2024 Planned End Date changed from 1 Jun 2031 to 1 Jun 2025.
- 12 Feb 2024 Planned primary completion date changed from 1 Jun 2031 to 1 Jun 2025.
- 12 Feb 2024 Status changed from recruiting to active, no longer recruiting.